{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Xiang Y"],"funding":["National Center for Advancing Translational Sciences","National Institute of Allergy and Infectious Diseases","NCATS NIH HHS","NIAID NIH HHS","NHLBI NIH HHS","National Heart Lung and Blood Institute","National Institute of General Medical Sciences","NIGMS NIH HHS"],"pagination":["6966-6980.e23"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11748749"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["187(24)"],"pubmed_abstract":["Pathogens constantly evolve and can develop mutations that evade host immunity and treatment. Addressing these escape mechanisms requires targeting evolutionarily conserved vulnerabilities, as mutations in these regions often impose fitness costs. We introduce adaptive multi-epitope targeting with enhanced avidity (AMETA), a modular and multivalent nanobody platform that conjugates potent bispecific nanobodies to a human immunoglobulin M (IgM) scaffold. AMETA can display 20+ nanobodies, enabling superior avidity binding to multiple conserved and neutralizing epitopes. By leveraging multi-epitope SARS-CoV-2 nanobodies and structure-guided design, AMETA constructs exponentially enhance antiviral potency, surpassing monomeric nanobodies by over a million-fold. These constructs demonstrate ult"],"journal":["Cell"],"pubmed_title":["Adaptive multi-epitope targeting and avidity-enhanced nanobody platform for ultrapotent, durable antiviral therapy."],"pmcid":["PMC11748749"],"funding_grant_id":["R01 AI163011","75N93021C00014","R01 HL169500","P50 GM082251","UL1 TR004419","R35 GM137905","R21 AI184080"],"pubmed_authors":["Ranzenigo A","Pham ND","Shen J","van Leent MMT","Benjamin J","Garcia-Sastre A","Teunissen AJP","Sang Z","Xu J","Zhang P","Shi Y","Diaz-Tapia R","White KM","Huang W","Taylor DJ","Xiang Y","Rodriguez ML","McGovern BL"],"additional_accession":[]},"is_claimable":false,"name":"Adaptive multi-epitope targeting and avidity-enhanced nanobody platform for ultrapotent, durable antiviral therapy.","description":"Pathogens constantly evolve and can develop mutations that evade host immunity and treatment. Addressing these escape mechanisms requires targeting evolutionarily conserved vulnerabilities, as mutations in these regions often impose fitness costs. We introduce adaptive multi-epitope targeting with enhanced avidity (AMETA), a modular and multivalent nanobody platform that conjugates potent bispecific nanobodies to a human immunoglobulin M (IgM) scaffold. AMETA can display 20+ nanobodies, enabling superior avidity binding to multiple conserved and neutralizing epitopes. By leveraging multi-epitope SARS-CoV-2 nanobodies and structure-guided design, AMETA constructs exponentially enhance antiviral potency, surpassing monomeric nanobodies by over a million-fold. These constructs demonstrate ult","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Nov","modification":"2026-06-01T20:14:58.296Z","creation":"2025-04-04T14:05:32.141Z"},"accession":"S-EPMC11748749","cross_references":{"pubmed":["39447570"],"doi":["10.1016/j.cell.2024.09.043"]}}